Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;13(2):547-567.
doi: 10.1007/s13346-022-01231-5. Epub 2022 Sep 21.

Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina

Lixiang Wang  1 , Hui Zhang  2
Affiliations
Review

Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina

Lixiang Wang et al. Drug Deliv Transl Res. 2023 Feb.

Abstract

In recent decades, the growing of the aging population in the world brings increasingly heavy burden of vision-threatening retinal diseases. One of the biggest challenges in the treatment of retinal diseases is the effective drug delivery to the diseased area. Due to the existence of multiple anatomical and physiological barriers of the eye, commonly used oral drugs or topical eye drops cannot effectively reach the retinal lesions. Innovations in new drug formulations and delivery routes have been continuously applied to improve current drug delivery to the back of the eye. Unique ocular anatomical structures or physiological activities on these ocular barriers, in turn, can facilitate drug delivery to the retina if compatible formulations or delivery routes are properly designed or selected. This paper focuses on key barrier structures of the eye and summarizes advances of corresponding drug delivery means to the retina, including various local drug delivery routes by invasive approaches, as well as systemic eye drug delivery by non-invasive approaches.

Keywords: Blood-retinal barrier; Ocular drug delivery; Prodrug; Retina; Sustained release formulations.

PubMed Disclaimer

References

    1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64. https://doi.org/10.2337/dc11-1909 . - DOI
    1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-116. https://doi.org/10.1016/s2214-109x(13)70145-1 . - DOI
    1. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2): e144-e160. https://doi.org/10.1016/s2214-109x(20)30489-7 .
    1. Maharjan P, Cho KH, Maharjan A, et al. Pharmaceutical challenges and perspectives in developing ophthalmic drug formulations. J Pharm Investig. 2019;49(2):215–28. https://doi.org/10.1007/s40005-018-0404-6 . - DOI
    1. Wang L, Zhou MB, Zhang H. The emerging role of topical ocular drugs to target the posterior eye. Ophthalmol Therapy. 2021;10(3):465–94. https://doi.org/10.1007/s40123-021-00365-y . - DOI

Publication types

LinkOut - more resources